GSK has acquired an approval for ‘Incruse Ellipta,’ reinforcing its COPD lineup

Published: 2015-07-01 14:34:35

Updated: 2015-07-01 14:34:35

GSK is in the heat of reinforcing its respiratory disease treatment pipeline. It is working on a long-acting anticholinergic(LAMA) drug this time.

The company has acquired a sales approval for the LAMA-only chronic obstructive pulmonary disease(COPD) treatment, ‘Incruse Ellipta(umeclidinium),’ from the Ministry of Food and Drug Safety on the 25^th.

Incruse Ellipta is a LAMA-only drug excluding...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.